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Abstract 
Background: Toxoplasma is an important source of foodborne hospitalization with no safe and effective 
therapy against chronic or congenital Toxopalsmosis. Atovaquone is a drug of choice but not approved 
for use in congenital Toxoplasmosis. We hypothesized atovaquone to be safe and effective against feto-
maternal Toxoplasmosis. 
Material/Methods: Programmed pregnant mice were i.p. infected with 50–2400 Tachyzoites from Type II 
strain (clone PTG). Dams were treated daily with atovaquone or sham and monitored for pain, and 
complications. 
Results: Dams developed pain related abdominal hypersensitivity (allodynia) to mechanical stimuli in a 
Tachyzoites dose dependent manner. Infected dams were anemic and exhibited ascities and severe 
hepatitis (score 3.6±0.01 on scale 0 – normal to 4 – severe) with influx of inflammatory and plasma cells, 
multinucleated dysplastic hepatocytes and necrosis. In addition, dams expressed mild to severe 
pancreatitis with mononuclear cell invasion, loss of islets and necrosis. This was consistent with 
splenomegaly (X3 Fold), and massive infiltration of epithelioid cells and loss of germinal structure. Colon 
became significantly shortened in length (p < 0.01) with semi-normal content. Pathological manifestation 
included, shortening of crypts with numerous microabscess formations, infiltration of lymphocytes, and 
macrophages. The severe clinical complications led to abortion (50%), early birth (25%) or still birth (25%) 
consistent with the high dose of Tachyzoites inoculation. Atovaquone treatment partially but significantly 
protected the dams from the severity of hepatitis, splenomegaly, colitis, myocarditis, and pain related 
responses as well as fetal demise. 
Conclusions: This is a valuable model for therapeutic evaluation of feto-maternal Toxoplasmosis and 
gastrointestinal complications. Atovaquone protects dams and their fetuses against some infectious/
inflammatory aspects of the disease. 
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Summary
 Background: Toxoplasma is an important source of foodborne hospitalization with no safe and effective thera-
py against chronic or congenital Toxopalsmosis. Atovaquone is a drug of choice but not approved 
for use in congenital Toxoplasmosis. We hypothesized atovaquone to be safe and effective against 
feto-maternal Toxoplasmosis.
 Material/Methods: Programmed pregnant mice were i.p. infected with 50–2400 Tachyzoites from Type II strain (clone 
PTG). Dams were treated daily with atovaquone or sham and monitored for pain, and complications.
 Results: Dams developed pain related abdominal hypersensitivity (allodynia) to mechanical stimuli in a 
Tachyzoites dose dependent manner. Infected dams were anemic and exhibited ascities and se-
vere hepatitis (score 3.6±0.01 on scale 0 – normal to 4 – severe) with influx of inflammatory and 
plasma cells, multinucleated dysplastic hepatocytes and necrosis. In addition, dams expressed mild 
to severe pancreatitis with mononuclear cell invasion, loss of islets and necrosis. This was consis-
tent with splenomegaly (X3 Fold), and massive infiltration of epithelioid cells and loss of germi-
nal structure. Colon became significantly shortened in length (p<0.01) with semi-normal content. 
Pathological manifestation included, shortening of crypts with numerous microabscess formations, 
infiltration of lymphocytes, and macrophages. The severe clinical complications led to abortion 
(50%), early birth (25%) or still birth (25%) consistent with the high dose of Tachyzoites inocula-
tion. Atovaquone treatment partially but significantly protected the dams from the severity of hep-
atitis, splenomegaly, colitis, myocarditis, and pain related responses as well as fetal demise.
 Conclusions: This is a valuable model for therapeutic evaluation of feto-maternal Toxoplasmosis and gastrointes-
tinal complications. Atovaquone protects dams and their fetuses against some infectious/inflam-
matory aspects of the disease.
 key words: feto-maternal Toxoplasmosis • gastrointestinal • pregnancy • hepatitis • atovaquone
 Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/883342
 Word count: 4045
 Tables: 1
 Figures: 7
 References: 41
 Author’s address: Helieh S. Oz, Department of Physiology, and Internal Medicine, MS635 University of Kentucky Medical Center, 
800 Rose Street, Lexington, KY 40536, U.S.A., e-mail: hoz2@email.uky.edu
Authors’ Contribution:
 A Study Design
 B Data Collection
 C Statistical Analysis
 D Data Interpretation
 E Manuscript Preparation
 F Literature Search
 G Funds Collection
Received: 2012.03.05
Accepted: 2012.05.10
Published: 2012.09.01
BR337
Basic Research
WWW.MEDSCIMONIT.COM© Med Sci Monit, 2012; 18(9): BR337-345
PMID: 22936182
BR
Current Contents/Clinical Medicine • IF(2010)=1.699 • Index Medicus/MEDLINE • EMBASE/Excerpta Medica • Chemical Abstracts
Background
Toxoplasma gondii, an obligate intracellular protozoan, is an 
important source of foodborne hospitalization. Toxoplasma 
infects humans and animals, specifically in impoverish and 
disadvantage populations. Toxoplasmosis in immunocom-
petent individuals is usually asymptomatic or manifested 
as flu like syndrome, but outcomes can include severe im-
pediment in immunocompromised hosts as well as fetus-
es leading to demise and death [1]. It is estimated that 
1,500,000 cases of Toxoplasmosis occurs in the U.S.A each 
year, and about 15% of these cases show clinical symptoms 
[2]. Toxoplasmosis reactivation occurs primarily during 
pregnancy and in AIDS and in immunocompromised in-
dividuals when cysts rupture. Congenital Toxoplasmosis 
in humans as well as animals (e.g. sheep and goats) is initi-
ated by the transplacental transmission of organisms dur-
ing maternal infection [3]. The congenital transmission of 
Toxoplasmosis was first reported in a 3 day old infant from 
New York in 1939 [4], and the importance of maternal fe-
tal transmission has long been recognized [5]. Congenital 
Toxoplasmosis leads to spontaneous abortion, intrauterine 
fetal death or severe congenital defects, such as encepha-
litis, hydrocephaly and chorioretinitis [6]. Toxoplasma in-
vades the central nervous system (CNS) with adverse affect 
in brain neuro-structural development and pathological 
as well as psycho-behavioral alteration leading to mental 
retardation [7–9]. More recently, maternal exposure to 
Toxoplasma organisms has been linked to a potential in-
creased risk for schizophrenic episodes and this hypothe-
sis has received a significant media attention.
Current therapy against Toxoplasmosis includes atovaquone 
(hydroxy-1,4-naphthoquinone) which is an FDA approved 
treatment but not in use for congenital Toxoplasmosis [10]. 
Atovaquone has been proven to be effective against oppor-
tunistic diseases such as Pneumocystis carinii pneumonia [11], 
malarial infections [12], and Babesia microti causative of hu-
man babesiosis [13,14]. So far, there is no safe and effective 
therapy (FDA approved) against congenital Toxoplasmosis 
or any drug capable of eliminating the persistent, chronic 
Toxoplasma infection. Spiramycin alone or associated with 
pyrimethamine-sulfadoxine are used to prevent transfer of 
Toxoplasma from the actively infected mother to the fetus. 
However, this approach is not always effective and associat-
ed with unwanted side effects [15–18].
The congenital Toxoplasmosis models are induced by the 
oral inoculation of Toxoplasma cysts or Tachyzoites from 
infected animals [19] or intraperitoneal injection of cysts 
from ME49 strain [20]. Consequently, a simple and reliable 
model for Toxoplasmosis induced feto-maternal complica-
tions is highly desirable to study the progression of disease 
and to investigate the therapeutic modalities in the model.
The objectives of this study were to: a) to develop a fetal ma-
ternal model to present moderate to severe gastrointesti-
nal Toxoplasmosis complications during the pregnancy for 
the use in drug evaluation and b) to study efficacy of atova-
quone against Toxoplasma infection in the model.
Therefore, it was hypothesized that atovaquone to be safe 
and effective against feto-maternal complications as conse-
quences of Toxoplasmosis in a murine pregnancy model.
Material and Methods
Toxoplasma gondii propagation
Type II isolates of Toxoplasma including ME-49 strain is pre-
dominantly discovered in human congenital Toxoplasmosis 
[21]. For this study, Toxoplasma Tachyzoites from PTG 
strain (ME-49, ATCC50841™) were originally cloned and 
propagated [22] and kindly provided by Dr. Daniel Howe, 
PhD, Maxwell H Gluck Equine Research Center, College 
of Agriculture, University of Kentucky. Briefly, Tachyzoites 
were cultured by serial passage in bovine turbinate cells 
and maintained in minimum essential medium (MEM-RS, 
HyClone Labs, Inc.) supplemented with 4% fetal clone III 
(HyClone, Labs, Inc.), Penicillin/Streptomycin/Fungizone 
(BioWhittaker, Inc.), and non-essential amino acids solu-
tion (HyClone, Labs, Inc.). Upon disruption of the host cell 
monolayer, extracellular Tachyzoites were harvested and 
purified from host cell debris by filtration through 3.0 µm 
membranes. Tachyzoites were enumerated in a hemocy-
tometer and suspended in phosphate buffer saline (PBS) 
to the appropriate concentrations for inoculation. To en-
sure Tachyzoites viability, inoculums were given intraperi-
toneally (i.p.) in 100 µl volume and within 1 h of harvest.
Murine model
This investigation was conducted according to the guide-
lines and approved by the Institutional Biosaftey Committee 
(IBC) and Institutional Animal Care and use committee 
(IACUC) at University of Kentucky Medical Center which 
is certified by the American Association of Accreditation of 
Laboratory Animal Care (AAALAC).
On day 1 of programmed pregnancy, 9 weeks old CD1 mice 
were purchased from Charles River Lab Inc. (Wilmington, 
MA) and housed individually in micro-isolator cages in a 
pathogen free environment. The room was maintained 
at 22°C with a 12:12-hr light:dark cycle at the Maxwell H. 
Gluck Equine Research Center Laboratory Animal Facility 
at the University of Kentucky. Dams were fed irradiated ro-
dent chow and sterilized drinking water ad libitum. After 5 
days acclimation, dams were weighed and ear-punched for 
appropriate identification.
To establish the model, dams were assigned into 6 animals 
per each group, and injected with 100 µl of Tachyzoites from 
0–50–100 and then 300–600–1200–2400 organisms (at pro-
portion of about 2 fold increments) given i.p. using 0.5 ml 
insulin syringes. Control dams (group 7) received 100 µl 
sham vehicle injection with sterile PBS. Animals were mon-
itored daily 3 times for physical appearance, distress, pain, 
and vaginal discharge to detect abortion, early delivery, or 
gastrointestinal complications [23]. The experiment was 
terminated on gestation day 16 before the possible early or 
premature birth to study the feto-maternal complications. 
For further drug evaluation we chose a cutoff dose of 600 
Tachyzoites inoculations where animals developed a mod-
erately severe feto-maternal Toxoplasmosis.
Atovaquone treatment
Atovaquone is currently used as a drug of choice against 
Toxoplasmosis but not tested in pregnancy. In order to study 
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efficacy of atovaquone against Toxoplasmosis in pregnancy, 
dams were divided into 2 groups. One group received ato-
vaquone (hydroxy-1,4-naphthoquinone) incorporated into 
daily diet as indicated in our previous publications [13,14]. 
Control group received sham treatment (inert talcum pow-
der). The treatment was initiated on Day 5 of pregnancy 
and continued until day 16 when dams were euthanatized. 
On day 8 of pregnancy dams on treatment or sham con-
trol arms were further divided into 3 subgroups of 6–8 an-
imals and were inoculated each with 0 (PBS), 300, or 600 
Tachyzoites. Pregnant animals voluntarily consumed the 
diet with no major changes in their appearance, food con-
sumption or weight/loss gain.
Sample collection
At the end of study dams were weight and euthanatized using 
Co2 inhalation. Immediately, their chests were opened and 
blood from right ventricle collected into microtainer (BD 
Biosource, Rockville, MD). Sera were separated and stored 
frozen at –80°C. The splenic weight and length were record-
ed. Organs including liver, pancreas, spleen, heart and uter-
us were excised and weighed. Sections of these tissues were 
flash frozen in liquid nitrogen and stored at –80°C for fu-
ture studies. Live fetuses were removed from uteri, count-
ed, weighed and their length measured from crown to the 
base of the tail using a digital caliper.
Histopathological Examination
Colonic tissue and H&E staining
Colonic tissues were flushed with PBS (pH 7.2) and a por-
tion from proximal and distal colonic tissue was fixed in 
10% neutral formalin for histological examinations. The 
remainder was snap-frozen in liquid nitrogen and stored 
at –80°C. The formalin fixed sections were processed and 
stained with hematoxylin and eosin (H&E), and slides evalu-
ated by Ziess light microscopy. Severity of colitis was assessed 
with a histological semi-quantitative grading score and per-
formed in a blinded fashion. The scores were based on his-
topathological features with a numeric value (0 – normal 
to 4 – severe) assigned according to the tissue involvement 
[24] that corresponded to either of the following criteria:
Grade 0 –  No detectable lesions, no inflammatory cells, nor-
mal mucosal appearance.
Grade 1 –  Focal inflammatory infiltrate in the mucosa.
Grade 2 –  Mild multi-focal inflammation with moderate ex-
pansion of the mucosa.
Grade 3 –  Moderate multi-focal inflammation with moder-
ate expansion of the mucosa.
Grade 4 –  Severe diffuse inflammation with crypt epitheli-
um disruption and ulceration.
Hepatic tissues
A small portion of the right lobe from hepatic tissues was 
placed in cassettes and fixed with 10% neutral buffered 
formalin. The specimens were dehydrated and embed-
ded in paraffin, and tissue sections of 5µm were stained by 
Hematoxylin Eosin (H&E). Each slide was evaluated un-
der light microscopy [25]. Hepatic lesions were graded on 
a scale of 0 to 4+, based on degeneration, inflammation, 
and necrosis as follows:
Grade 0 –  Represented no detectable lesions, no degener-
ation, infiltration of inflammatory cells, normal 
tissue appearance.
Grade 1 –  Focal infiltration of inflammatory cells in the tis-
sue, and hepatocytes degeneration.
Grade 2 –  Mild multi-focal infiltration of inflammatory cells, 
and hepatocytes degeneration.
Grade 3 –  Moderate multi-focal infiltration of inflammato-
ry cells, and hepatocytes degeneration.
Grade 4 –  Severe diffuse infiltration of inflammatory cells, 
and necrosis.
Giemsa staining
Giemsa is a delicate polychromatic stain that reveals a fine 
nuclear detail of Toxoplasma organisms. Giemsa stain con-
tains Methylene Blue Azure Basic dyes combined with Eosin 
Acidic dyes. The deparaffinized slide sections were placed 
into the polychromatic Giemsa (40drops/50ml distilled wa-
ter) to stain nuclei of the Toxoplasma organisms and to permit 
differentiation among the cells. Then, the slides were depre-
ciated in 1% Glacial Acetic Acid, dehydrated in alcohol and 
xylene series and mounted in synthetic resin on the slides.
Immunohistochemical (IHC) staining
IHC was performed using Dalo EnVision+ System-HRP 
(DAB) kit. Anti-Toxoplasma antibody and IHC procedure 
were kindly provided by David S. Lindsay, PhD at University 
of West Virginal. Briefly, paraffin-embedded sections were 
cut, deparaffinized with xylene, rehydrated in alcohol baths, 
washed in PBS and 0.1% BSA, quenched endogenous per-
oxidase activity by incubating in 3% hydrogen peroxide in 
methanol for 30 min, then blocked with rabbit serum (Dako 
#N1699), for 30 min. The sections were incubated with poly-
clonal anti-Toxoplasma antibody, diluted 1:500 for 90 min 
and developed with DAB-Chromogen (Dako Carpenteria, 
CA) for about 5 min until signal developed. Slides were 
subsequently counterstained with hematoxylin then am-
monia treated and dehydrated stepwise through alcohol, 
and cleared with xylene.
Behavioral test: assessment of pain related mechanical 
allodynia by testing abdominal withdrawal threshold
Abdominal withdrawal responses to mechanical stimuli were 
quantified with von Frey monofilaments (Semmes-Weinstein 
Anesthesiometer Kit, model #18011, Wood Dale, IL) ac-
cording to our previous publication with some modifica-
tion [26]. Briefly, mice were placed into plastic enclosures 
on the custom made screen meshed platform. The monofil-
ament range used for this study included 5 different inten-
sities corresponding to (hair diameter) gram force [(4.08) 
1.0 g; (3.61) 0.4 g; (3.22) 0.166 g; (2.83)0.07; (2.36) 0.02g 
forces]. Testing for mechanical stimulation was performed 
on the first and the last day of treatment. A single trial con-
sisted of 5 applications of the each filament used once ev-
ery 6 seconds to allow the dam to cease any response and 
return to an inactive position. Mean values of the percent-
age of responses of the abdominal withdrawal to each fila-
ment (mean withdrawal/5 ×100) were used as % scores in 
this study. This behavioral test reflected basal level for re-
flex score and any possible sensory changes observed in 
the treated mice. Total 4 dams were tested per each group.
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Statistical analysis
Results are expressed as mean ±SEM unless otherwise stat-
ed. Data was evaluated with ANOVA followed by appropri-
ate post hoc test (Tukey compared all pairs) using GraphPad 
Instat version 3 for Windows (GraphPad Software, San Diego, 
CA). Statistical significance was set at p<0.05.
results
Model for feto-maternal Toxoplasmosis
To establish the model, dams were infected with single in-
oculum of PTG strain Tachyzoites ranging from 100 to 2400 
during the 2nd trimester of pregnancy. Dams infected with 
low dose (T-50) showed no significant clinical symptoms. 
While, those infected with higher number of Tachyzoites 
developed moderate to severe clinical complications in a 
dose dependent manner leading to abortion (4/8, 50%), 
early birth (1/4, 25%) or still birth (1/4, 25%).
Pain related abdominal response to stimuli
Infected dams showed significant increases in abdominal 
response to the mechanical stimuli (allodynia) with von 
Frey monofilaments. The elevated hypersensitivity showed a 
Tachyzoites dose dependent response with about 4 fold incre-
ments in dams receiving the highest dose (T-2400, p<0.001) rep-
resenting the most severe reaction to the stimuli (Figure 1A).
Excess body weight gain
Both uninfected normals as well as infected dams gained 
weight. However, dams infected with high doses of 
Tachyzoites (T-1200 to T-2400) showed a more severe ede-
ma, ascities, and hydrothorax with a significant excess body 
weight gain leading to fetal abortion or mummified embryos. 
Ascities consisted of a bright to bloody fluid and was main-
ly noted in the peritoneal and chest cavities (pneumotho-
rax) and correlated with the higher doses of Tachyzoites.
Anemia
Infected dams became anemic with pale mucosa (hemato-
crit: p<0.01 T-2400 Figure 2), in addition to hydrothorax 
and ascities. This was consistent with the splenomegaly with 
about X3 fold increases in splenic weight (Figure 3A) and 
length (Figure 3C) in the infected dams mainly due to the 
scavenging infected cells by the splenic tissues and the se-
vere immune response to infection, demonstrating massive 
infiltration of epithelioid cells, and engulfed infected mac-
rophages in conjunction with loss of germinal structure in 
spleen in a dose dependent manner.
Hepatic and pancreatic pathology
Hepatic tissue became pale in color and weight increased 
due to inflammation. Infected dams developed hepatitis 
(scale 0 – normal to 4 – severe, T-1200=3.6±0.1 p<0.001) 
presenting portal lobular influx of inflammatory and plas-
ma cells, multinucleated “dysplastic” hepatocytes and mild 
to severe hepatic necrosis. These lesions were in a dose de-
pendent manner and correlated with the number of inoc-
ulated Tachyzoites (Figure 4A). In addition, dams showed 
mild to moderately severe pancreatitis with mononuclear 
cell invasion and loss of islets (not shown).
Cardiac pathology
Infected dams developed a mild to moderate myocardial ne-
crosis, fibrin deposit, and infiltration of inflammatory cells 
(Figure 5). Small pseudocysts to elongated cysts were detect-
ed with a few to numerous bradyzoites embedded with ag-
gregates of macrophages, plasma and monocytes infiltration. 
The cysts and occasional free organisms were detected in 
the heart, hepatic, and splenic tissues which were confirmed 
with Giemsa and immunohistochemical techniques (IHC).
Fetal weight and length
Dams infected with low doses of Tachyzoites (T-50 to 
T-300) did not show a significant differences between the 
Figure 1.  Percent pain related abdominal response 
to Von Frey mechanical stimuli to 
0.166 GM force. (A) Dose dependent 
abdominal response from dams 
infected with Tachyzoites (T-600 to 
T-2400) compared to normal Controls 
demonstrating increased hypersensitivity 
to stimuli. (B) Atovaquone treatment 
ameliorated hypersensitivity to stimuli 
(allodynia) in infected dams (T-600).
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Figure 2.  Infected dams had pale mucosa and became anemic as 
demonstrated by significant decreases in hematocrit values 
in a dose dependent manner (controls vs. T-600 p<0.05, 
Controls vs. T-1200 and T-2400 p<0.01).
50
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0
Control T-600 T-1200 T-2400
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Hematocrit
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appearance, fetal number, weight and length of the live fe-
tuses (p>0.05, NS). In contrast those dams inoculated with 
the high doses (T-1200 toT-2400) developed more progres-
sive disease leading to abortion, or intrauterine fetal de-
mise, and still birth (Figure 6A). Occasionally organisms 
were detected in the uterine tissue from infected dams 
with high dose of Tachyzoites by means of IHC (Figure 6B). 
Fetal weight (Figure 7A) was significantly affected in infect-
ed dams in a dose dependent manner leading to retarded 
and/or fetal loss.
Therefore, based on the above obtained data, a cutoff at 
600 Tachyzoites (T-600) per inoculum was established to in-
duce a moderately severe feto-maternal Toxoplasmosis in 
the model for further drug evaluation.
Atovaquone therapy in pregnancy model
Overall, atovaquone treated uninfected control dams showed 
no major differences compared to untreated normal con-
trols (sham injected) for the parameters measured, and 
Figure 4.  H&E stained sections from hepatic tissues 
were scored from normal (0) to severe 
(4) hepatitis (A). Atovaquone treatment 
significantly ameliorated the lesions in 
dams and protected against hepatitis as 
consequences of Toxoplasmosis (B).
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Figures 5.  H&E stained cardiomyocytes from 
infected Dam and cardiac weight. 
Infected dams developed mild to 
moderate myocarditis (A) with 
infiltration of inflammatory cells (H&E 
staining). Cardiac weight increased 
in infected dams and atovaquone 
treatment attenuated pathological 
inflammatory response and excess 
weight (B).
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Figure 3.  Splenic weight (A) and length (C) significantly increased in infected dams and partially but significantly improved in atovaquone treated 
animals (B, D, p<0.05).
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kept a normal status. Whereas, atovaquone treated and in-
fected dams showed no significant improvement in their 
excess body weight gain compared to infected (untreated) 
animals (Table 1).
Pain related abdominal response to stimuli and atovaquone 
therapy
Infected dams (T-600) showed a significant pain related 
abdominal hypersensitivity (p<0.05) to mechanical stimuli 
(Figure 1B). In contrast, atovaquone treatment attenuated 
this neuropathological reactions to a normal level (p<0.05) 
indicating efficacy of atovaquone to ameliorate pain relat-
ed clinical symptoms of infection/inflammatory induced 
hypersensitivity (Figure 1B).
Anemia, splenomegaly and atovaquone therapy
Atovaquone did not improve hematocrit or anemia in infect-
ed and treated dams (Table 1). Infected dams developed en-
larged fragile splenic tissues. In contrast, atovaquone ther-
apy partially but significantly attenuated splenomegaly and 
the pathological increases in the splenic weight and length 
in infected dams (Figure 3B, D).
Pathology and atovaquone therapy
Hepatitis
Infected dams (T-600) developed moderately severe he-
patic lesions (score of 3.3±0.01 P<0.001) presenting, scat-
tered dysplastic hepatocytes and moderate to severe hepatic 
Figure 6.  Uteri from infected (red arrow) and 
uninfected (blue arrow) dams (A) similar 
to atovaquone treated ones (not shown 
here). Immunohistochemical staining 
demonstrating infected uteri. Arrows 
point at the organisms (B).
A B
Figure 7.  Fetal weight significantly decreased in 
a dose dependent response due to the 
infection (A). Atovaquone treatment 
returned the fetal weight to a normal 
value (B).
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Tissues from Dams Control Infected Infected + Treated P< value
Body Weight gain (g)  14.2±0.6***  22.8±1  22.5±0.9 ***<0.001
Colonic length (cm)  10.25±025**  8.6±0.27  8.6±0.5 **<0.01
Colonic weight/ atrophy (mg) 250±10**  200±10**,*  230±10* **<0.01, *<0.05
Hematocrit (%)  44.5±1.2*  37±1.4  34.7±3.3 *<0.05
Utri weight (g)  11.6±0.5*  13.9±0.7*  12.8±1 *<0.05
Hepatic weight (g)  1.78±0.24**,*  3.4±0.13**  3.1±0.34* **<0.01, *<0.05
Table 1. Dams were infected with Toxoplasma Tachyzoites (T-600) on pregnancy and treated with atovaquone daily.
P value – * <0.05; ** <0.01; ***<0.001.
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necrosis and excess weight due to infiltration of inflam-
matory cells (p<0.01) (Figure 4). Atovaquone partially but 
significantly attenuated these pathological manifestations 
and improved hepatic structural integrity (score 2.8±0.1 
p<0.05) (Figure 4B) as well as the excess hepatic weight 
(p<0.05) (Table 1).
Colonic pathology
Colonic tissues from infected dams (T-600) were significantly 
shortened in length (10.4±0.2 vs. infected 8.7±0.6 cm p<0.01) 
and decreased in weight (p<0.01) presumably through the 
mechanism of sloughing off of the brush boarder in infected 
dams (Table 1). Colonic pathology manifested with shorten-
ing of crypts with numerous microabscess formations, and 
infiltration of inflammatory cells, including lymphocytes, 
and macrophages with few scattered neutrophils detect-
ed in the mucosal area. Atovaquone extensively protected 
dams from colonic inflammatory and necrotic/atrophic re-
sponses to the infection (p<0.05). In addition, a mild to se-
vere pancreatitis was diagnosed in infected dams (T-600 vs. 
Normal p<0.05) with invasion of mononuclear cells and loss 
of islets (not shown). Similarly, atovaquone treatment par-
tially but significantly protected the dams from these path-
ological and inflammatory aspects of the GI Toxoplasmosis.
Cardiac pathology
Infected dams developed a mild myocardial necrosis, fibrin 
deposit, and infiltration of inflammatory cells as shown in 
H&E staining (Figure 5). Small to elongated cysts were de-
tected with a few to numerous bradyzoites embedded with 
aggregates of macrophages and plasma and monocytes in-
filtration. This was consistent with the detection of cysts and 
free organisms in the heart, hepatic as well as the splenic 
tissues which were confirmed with Giemsa and IHC tech-
niques. Atovaquone significantly improved myocardial pa-
thology and excess cardiac weight (Figure 5B).
Fetal weight
Infected dams (T-600) showed fetal retardation and spo-
radic cases of still birth. In contrast, atovaquone treatment 
protected nested fetuses in uterine from weight loss, retar-
dation and demise (Figure 7B).
discussion
Two billion people worldwide are predicted to have 
Toxoplasmosis, frequently with unknown lifelong health 
consequences [28]. Toxoplasma is considered as the 3rd ma-
jor cause of foodborne diseases’ hospitalization and death 
in the U.S.A [27]. Toxoplasmosis can have mild effects on 
immunocompetent to very severe pathological damage in 
congenital transmission. Congenital Toxoplasmosis is caused 
by a reactivation, or as an acquired infection during preg-
nancy is known to be associated with an altered balance 
of immune response rather than direct noxious actions of 
the pathogen [3–5]. Feto-maternal Toxoplasmosis results 
in an extensive immune and inflammatory response to the 
organisms in the gastrointestinal tissues with a low number 
of pathogenic burdens as demonstrated in this pregnan-
cy model. Indeed, managing the inflammation is vital in 
order to prevent damage to the host and the nested fetus 
during the infection. While, uncontrolled inflammatory re-
sponse in Toxoplasmosis can be fatal during the pathogen-
ic clearance [29].
Our findings with this murine system support the model in 
which fetal health is compromised by the invasion of patho-
gens and encountered inflammatory responses from infected 
dam through the mechanism of transplacental transmission 
and in a dose dependent manner. A recent study indicates that 
a dose of 10,000 bradyzoites or 100 oocysts of the Prugniaud 
strain (Type II) to cause 50% congenital infection of the rat 
litters. In contrast, lactation alone did not support transmis-
sion of infection from dams to the neonates [19].
Pregnant women become infected by ingestion of oo-
cysts contaminated food, or consumption of cysts harbor-
ing bradyzoites-infected meat. Additionally, transplacental 
transmission is acquired by the reactivation of the chronic 
or latent infection due to the stressors including pregnan-
cy and immunosuppressors. In any circumstances, whether 
oocysts, cysts, (or Tachyzoites) are the origin of the infec-
tion the organisms transform to Tachyizoites and replicate 
in the organs to cause the infection. Then the Tachyzoites 
are required to bypass the transplacental blood barrier to 
invade the fetus and to compromise the embryonic devel-
opmental process.
The current model bypasses the requirement for oral pas-
sage and a large number of organisms by using direct intra-
peritoneal inoculation to cause feto-maternal Toxoplasmosis.
This model imitates well the Toxoplasma reactivation or con-
taminated blood transfusion and organ transplantation, and 
uses a fewer organisms than those required for an oral in-
fection. Additionally, this model eliminates the use of extra 
animals (mice or cats) to develop cysts or oocyts. Therefore, 
the present model mimics well the process of the intrauter-
ine infection, and evades the oral inoculation and the need 
for a large numbers of the organisms.
The majority of Toxoplasma strains so far isolated from 
North America and Europe belong to three clonal lineag-
es I–III, of which types I and II are associated with con-
genital Toxoplasmosis [30]. For this study, we used type II 
Tachyzoites from PTG strain (ME-49) originally cloned and 
propagated [22] to initiate the infection. ME-49 genotype 
II strain is most frequently associated with the human dis-
ease including congenital Toxoplasmosis [21,30–33] and 
used in this study to develop the feto-maternal model for 
the drug evaluation.
Thus far, there is no safe and effective or FDA approved 
therapy against congenital Toxoplasmosis or any drug ca-
pable of eliminating the persistent, chronic infection [10]. 
Atovaquone is a drug of choice against Toxoplasmosis but 
not yet approved for the use in pregnancy or small children. 
As shown in this study, atovaquone was effective against com-
plications in the model and limited the inflammatory re-
sponses to Tachyzoites infection in organs such as cardiac, 
spleen, hepatic and colonic tissues and therefore protect-
ed the fetuses and the dams from the infection.
Atovaquone has been shown to be effective against 
Tachyzoites and cyst forms of Toxoplasma [12], Pneumocystis 
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carinii [11], Plasmodium Falciparum (12) and B. microti [13,14] 
organisms. Atovaquone is known to inhibit parasite and fun-
gal respiration by binding to the ubiquinol oxidation site of 
cytochrome bc1 complex [34] by affecting the mitochondri-
al function and collapsing their membrane [35]. The radio-
labelled tracing in man has proven that atovaquone mainly 
attaches to the plasma protein (99%) with a half life of 1.5 
to 3 days with 2 peaks; the 1st peak appears at 1–8 h and 2nd 
in 1–4 days after a single oral dose in human volunteers. In 
addition, surgical biliary tube insulation in patients dem-
onstrated that atovaquone is exclusively (94%) excluded 
from the body through the feces and it is not metabolized 
by humans [36]. Indeed, mice with a targeted gene muta-
tion in the interferon regulatory factor 8 when latently in-
fected with Toxoplasma, developed reactivated encephalitis, 
and those treated with atovaquone were protected against 
encephalitis and death [37]. Furthermore, atovaquone 
treatment was proven to be superior to the standard ther-
apy with pyrimethamine plus sulfadiazine or combination 
of pyrimethamine plus clindamycin based on the inflam-
matory responses in the brain parenchyma, and the num-
ber of the organisms located in the brain in a mice [37]. 
In addition, atovaquone was detectable in sera, brains, liv-
ers, and lungs from infected mice using high pressure liq-
uid chromatography (HPLC) and Mass Spectroscopy [37].
Generally, Toxoplasma disseminates from the gut through-
out the body, and the organisms seek refuge in the muscu-
lar tissue and CNS in cysts forms during the dormant stage 
[38]. It is known that extracellular Tachyzoites readily in-
fect the host leucocytes, monocytes and dendritic cells and 
expliting the host cells as “Trojan Horse” a) to disseminate 
throughout the body and to cross the placenta [39] as well 
as the blood brain barrier and b) to provide protection 
against host immune defense [40].
In this investigation, the model well mimicked the disease 
in the human pregnancy and atovaquone had a limited but 
significant protective effect against gastrointestinal compli-
cations in these animals. Here, dams demonstrated signif-
icant excess weight gain (p<0.001) due to the inflammato-
ry response to the infection. This is in accord with a recent 
retrospective cohort study in 194 infected pregnant wom-
en who gained more weight when compared to 785 unin-
fected moms (P<0.001) [41]. However, atovaquone had 
minor effect on the excess body weight gain in this model.
Thus, the feto-maternal and GI complications described 
here permitted us to evaluate the efficacy of atovaquone in 
this Toxoplasmosis pregnancy model. Atovaquone proved 
to be fairly safe and to protect against inflammatory aspects 
of the feto-maternal progression of Toxoplasmosis. These 
findings warrant further functional, biochemical and mo-
lecular mechanistic studies in the fetal development, and 
related syndrome and the use for development of new and 
effective therapies.
conclusions
This model can be used for therapeutic evaluation in feto-
maternal Toxoplasmosis and gastrointestinal complications. 
This study proves that atovaquone protects against some 
inflammatory aspects of gastrointestinal and feto-maternal 
Toxoplasmosis in this model.
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